Anupam Rama
Stock Analyst at JP Morgan
(4.34)
# 403
Out of 5,136 analysts
310
Total ratings
49.39%
Success rate
19%
Average return
Main Sectors:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Overweight | $179 → $177 | $134.51 | +31.59% | 20 | Jan 12, 2026 | |
| VERA Vera Therapeutics | Maintains: Overweight | $99 → $96 | $49.46 | +94.10% | 12 | Dec 19, 2025 | |
| COGT Cogent Biosciences | Maintains: Overweight | $65 → $67 | $37.93 | +76.64% | 9 | Dec 19, 2025 | |
| VOR Vor Biopharma | Maintains: Overweight | $43 → $40 | $14.66 | +172.85% | 2 | Dec 19, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $147 → $145 | $107.41 | +35.00% | 7 | Dec 19, 2025 | |
| NVAX Novavax | Maintains: Underweight | $7 → $6 | $8.11 | -25.97% | 1 | Nov 18, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $17 → $20 | $11.50 | +73.99% | 7 | Nov 18, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $29 → $32 | $29.27 | +9.33% | 6 | Nov 18, 2025 | |
| ENTA Enanta Pharmaceuticals | Initiates: Overweight | $17 | $13.68 | +24.31% | 1 | Nov 14, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $40 → $33 | $20.89 | +57.97% | 11 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $57 | $34.83 | +63.65% | 10 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $27 | $10.62 | +154.36% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $77 | $78.23 | -1.57% | 12 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $14.34 | +32.50% | 14 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $11 | $5.86 | +87.87% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $36 | $20.22 | +78.04% | 18 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $24 | $28.84 | -16.78% | 8 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $79 | $37.19 | +112.42% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 | $7.84 | +40.31% | 12 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $37 | $41.45 | -10.74% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.97 | - | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $21.65 | +10.85% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $49.21 | +62.57% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $117 | $23.98 | +387.91% | 3 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $51 | $19.48 | +161.87% | 12 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $27.99 | +57.23% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $38.65 | +3.49% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.31 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.72 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.32 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $6.60 | +96.97% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $90 | $5.68 | +1,484.51% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $4.62 | +5,311.26% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $15.30 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $63.82 | -9.12% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $20.44 | -41.29% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $6.73 | +449.78% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $84.76 | -35.11% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $14 → $38 | $10.25 | +270.73% | 13 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $8.28 | +238.37% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $28.20 | +91.49% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.36 | +12,303.53% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $17.16 | +57.34% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $361.31 | -62.08% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $9.73 | +393.32% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $15.69 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.05 | +2,757.14% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $75.97 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.53 | - | 2 | Jul 21, 2017 |
Neurocrine Biosciences
Jan 12, 2026
Maintains: Overweight
Price Target: $179 → $177
Current: $134.51
Upside: +31.59%
Vera Therapeutics
Dec 19, 2025
Maintains: Overweight
Price Target: $99 → $96
Current: $49.46
Upside: +94.10%
Cogent Biosciences
Dec 19, 2025
Maintains: Overweight
Price Target: $65 → $67
Current: $37.93
Upside: +76.64%
Vor Biopharma
Dec 19, 2025
Maintains: Overweight
Price Target: $43 → $40
Current: $14.66
Upside: +172.85%
Nuvalent
Dec 19, 2025
Maintains: Overweight
Price Target: $147 → $145
Current: $107.41
Upside: +35.00%
Novavax
Nov 18, 2025
Maintains: Underweight
Price Target: $7 → $6
Current: $8.11
Upside: -25.97%
ORIC Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $11.50
Upside: +73.99%
Olema Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $29 → $32
Current: $29.27
Upside: +9.33%
Enanta Pharmaceuticals
Nov 14, 2025
Initiates: Overweight
Price Target: $17
Current: $13.68
Upside: +24.31%
Syndax Pharmaceuticals
Nov 12, 2025
Maintains: Overweight
Price Target: $40 → $33
Current: $20.89
Upside: +57.97%
Nov 12, 2025
Maintains: Overweight
Price Target: $55 → $57
Current: $34.83
Upside: +63.65%
Nov 7, 2025
Maintains: Overweight
Price Target: $26 → $27
Current: $10.62
Upside: +154.36%
Nov 7, 2025
Maintains: Overweight
Price Target: $76 → $77
Current: $78.23
Upside: -1.57%
Nov 6, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $14.34
Upside: +32.50%
Nov 5, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $5.86
Upside: +87.87%
Nov 5, 2025
Maintains: Overweight
Price Target: $40 → $36
Current: $20.22
Upside: +78.04%
Oct 24, 2025
Upgrades: Overweight
Price Target: $15 → $24
Current: $28.84
Upside: -16.78%
Oct 23, 2025
Maintains: Overweight
Price Target: $74 → $79
Current: $37.19
Upside: +112.42%
Oct 20, 2025
Upgrades: Neutral
Price Target: $11
Current: $7.84
Upside: +40.31%
Sep 29, 2025
Maintains: Overweight
Price Target: $27 → $37
Current: $41.45
Upside: -10.74%
Sep 16, 2025
Downgrades: Neutral
Price Target: n/a
Current: $5.97
Upside: -
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $21.65
Upside: +10.85%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $49.21
Upside: +62.57%
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $23.98
Upside: +387.91%
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $19.48
Upside: +161.87%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $27.99
Upside: +57.23%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $38.65
Upside: +3.49%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $2.31
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.72
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $4.32
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $6.60
Upside: +96.97%
Aug 16, 2023
Maintains: Neutral
Price Target: $80 → $90
Current: $5.68
Upside: +1,484.51%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $4.62
Upside: +5,311.26%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $15.30
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $63.82
Upside: -9.12%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $20.44
Upside: -41.29%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $6.73
Upside: +449.78%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $84.76
Upside: -35.11%
Oct 11, 2021
Upgrades: Neutral
Price Target: $14 → $38
Current: $10.25
Upside: +270.73%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $8.28
Upside: +238.37%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $28.20
Upside: +91.49%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.36
Upside: +12,303.53%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $17.16
Upside: +57.34%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $361.31
Upside: -62.08%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $9.73
Upside: +393.32%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $15.69
Upside: -
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $1.05
Upside: +2,757.14%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $75.97
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $4.53
Upside: -